Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2024-04-02 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
2023年度独立董事述职报告（程志鹏）
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It details the independent director's attendance at board and shareholder meetings, participation in committees, opinions expressed, special powers exercised, communication with audit institutions, on-site work, communication with minority shareholders, and other duties performed during the year 2023. The content is a detailed report on the independent director's activities and responsibilities over the year, rather than a general annual report or financial statement. It is not an announcement or a brief summary but a comprehensive report on board/management information specifically related to the independent director's role and duties. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 4593 characters, which is sufficient for a detailed report rather than a mere announcement. No financial statements or earnings data are included, so it is not an Annual Report or Earnings Release. No audit opinions or certifications are the main focus, so it is not an Audit Report. Hence, the classification is MANG with high confidence.
2024-04-02 Chinese
2023年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised through a public stock issuance by Sichuan Zitonggong Pharmaceutical Co., Ltd. It includes specifics on the total amount raised, net proceeds, timing of fund receipt, usage amounts over multiple years, balance of remaining funds, and details on the purchase of financial products with idle funds. It also contains information on the special accounts for the raised funds, their closure, and compliance with regulatory requirements. The document references regulatory approvals and audit opinions related to the use of raised funds. The content is focused on the use and management of capital raised from investors, which aligns with a Capital/Financing Update. It is not an annual report, earnings release, or other financial statement, but a specialized report on fundraising and fund usage. The length and detail confirm it is the report itself, not just an announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-04-02 Chinese
利润分配管理制度
Governance Information Classification · 95% confidence The document is titled '利润分配管理制度' which translates to 'Profit Distribution Management System'. It details the company's policies, procedures, and rules regarding profit distribution, dividend payments, and related governance. It includes sections on decision-making processes, dividend policies, supervisory mechanisms, and disclosure requirements. The document is issued by the company's board and dated April 3, 2024. It is a detailed policy document rather than a financial report, earnings release, or announcement of voting results. It does not contain financial statements or earnings data, nor is it a notice of dividend amount or voting results. It is a governance-related document outlining internal rules and procedures related to profit distribution and shareholder returns. Therefore, it fits best under Governance Information (CGR). The document length (6613 characters) supports it being a full policy document rather than a brief announcement.
2024-04-02 Chinese
中汇会计师事务所（特殊普通合伙）关于四川梓橦宫药业股份有限公司年度募集资金存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "年度募集资金存放与使用情况鉴证报告" which translates to "Annual Verification Report on the Storage and Use of Raised Funds." It includes detailed information about the company's fundraising amount, usage, storage accounts, and compliance with regulatory requirements related to the management of raised funds. The document is prepared by a registered accounting firm providing an attestation on the company's use of raised funds for the year 2023. It references specific regulatory guidelines from the Beijing Stock Exchange and the China Securities Regulatory Commission. The content is focused on the verification and reporting of fundraising capital usage rather than a full annual report or earnings release. This type of document fits best under the category of Audit Report / Information (AR), as it is a standalone audit/verification report related to the company's fundraising activities and compliance, not the full annual report or other categories.
2024-04-02 Chinese
会计政策变更公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies by the company Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the nature of the accounting policy change, the date of change, the reasons for the change, and the approvals by the board and supervisory committee. The document is relatively short (1104 characters) and does not contain financial statements or detailed financial data. It is not a full annual or interim report, nor is it an audit report or earnings release. It is a regulatory announcement about accounting policy changes, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories and is not a full report itself.
2024-04-02 Chinese
关于2024年度公司及子公司向金融机构申请融资授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the application for a credit facility from financial institutions for the year 2024. It details the amount, purpose, and approval status of the credit application. The document includes information about the board meeting resolution approving the credit application and mentions compliance with stock exchange listing rules. There are no financial statements or detailed financial data presented, nor is this a report or transcript. The content focuses on financing activities and credit facility updates. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is short and it is not merely an announcement of a report publication, so it is not RPA or RNS. Confidence is high given the clear focus on financing and credit application.
2024-04-02 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.